Logo
x

Search

Subscribe Now

adc

ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in EU and Select International Territories

ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in E...

  • July 8, 2022
ADC Entered an Exclusive License Agreement with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Japan

ADC Entered an Exclusive License Agreement with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta (loncas...

  • January 18, 2022
PharmaShots Weekly Snapshots (October 25 - 29, 2021)

PharmaShots Weekly Snapshots (October 25 - 29, 2021)

  • October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

  • October 29, 2021
PharmaShots Interview: Pyxis Oncology's Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio

PharmaShots Interview: Pyxis Oncology's Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Fu...

  • April 26, 2021
Synaffix Expands its Existing Collaboration with ADC Therapeutics to Explore Two Additional Programs

Synaffix Expands its Existing Collaboration with ADC Therapeutics to Explore Two Additional Programs

  • July 24, 2020
Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs

    Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs

    • January 13, 2025
    Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

      Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

      • January 10, 2025
      ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

        ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Ly...

        • January 1, 2025
        Allink Biotherapeutics Secures $42M to Support the Development of Bispecific Antibody and ADC Pipeline

          Allink Biotherapeutics Secures $42M to Support the Development of Bispecific Antibody and ADC Pipeline

          • November 29, 2024
          PTC Therapeutics Reports the US FDA’s Accelerated Approval of its Gene Therapy for AADC Deficiency

            PTC Therapeutics Reports the US FDA’s Accelerated Approval of its Gene Therapy for AADC Deficiency

            • November 14, 2024
            IDEAYA Biosciences Nominates IDE034 as a Development Candidate Under Partnership with Biocytogen

              IDEAYA Biosciences Nominates IDE034 as a Development Candidate Under Partnership with Biocytogen

              • November 11, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.